Logo image of AADI

AADI BIOSCIENCE INC (AADI) Stock Fundamental Analysis

NASDAQ:AADI - Nasdaq - US00032Q1040 - Common Stock - Currency: USD

2.79  -0.07 (-2.45%)

Fundamental Rating

3

Taking everything into account, AADI scores 3 out of 10 in our fundamental rating. AADI was compared to 572 industry peers in the Biotechnology industry. The financial health of AADI is average, but there are quite some concerns on its profitability. While showing a medium growth rate, AADI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AADI has reported negative net income.
In the past year AADI has reported a negative cash flow from operations.
AADI had negative earnings in each of the past 5 years.
In the past 5 years AADI always reported negative operating cash flow.
AADI Yearly Net Income VS EBIT VS OCF VS FCFAADI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of AADI (-71.98%) is worse than 66.25% of its industry peers.
AADI has a Return On Equity (-89.57%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -71.98%
ROE -89.57%
ROIC N/A
ROA(3y)-50.74%
ROA(5y)-44.04%
ROE(3y)-60.48%
ROE(5y)-51.04%
ROIC(3y)N/A
ROIC(5y)N/A
AADI Yearly ROA, ROE, ROICAADI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5K 10K

1.3 Margins

AADI has a Gross Margin of 87.39%. This is amongst the best in the industry. AADI outperforms 90.76% of its industry peers.
AADI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AADI Yearly Profit, Operating, Gross MarginsAADI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

More info and screens

6

2. Health

2.1 Basic Checks

AADI does not have a ROIC to compare to the WACC, probably because it is not profitable.
AADI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AADI has more shares outstanding
AADI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AADI Yearly Shares OutstandingAADI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
AADI Yearly Total Debt VS Total AssetsAADI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

AADI has an Altman-Z score of -3.98. This is a bad value and indicates that AADI is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.98, AADI perfoms like the industry average, outperforming 42.45% of the companies in the same industry.
There is no outstanding debt for AADI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.98
ROIC/WACCN/A
WACC9.44%
AADI Yearly LT Debt VS Equity VS FCFAADI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

AADI has a Current Ratio of 4.89. This indicates that AADI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.89, AADI is in line with its industry, outperforming 53.11% of the companies in the same industry.
A Quick Ratio of 4.54 indicates that AADI has no problem at all paying its short term obligations.
The Quick ratio of AADI (4.54) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.89
Quick Ratio 4.54
AADI Yearly Current Assets VS Current LiabilitesAADI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.39% over the past year.
AADI shows a small growth in Revenue. In the last year, the Revenue has grown by 7.78%.
AADI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.85% yearly.
EPS 1Y (TTM)3.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.33%
Revenue 1Y (TTM)7.78%
Revenue growth 3Y17.53%
Revenue growth 5Y3.85%
Sales Q2Q%21.03%

3.2 Future

AADI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.04% yearly.
Based on estimates for the next years, AADI will show a very strong growth in Revenue. The Revenue will grow by 42.64% on average per year.
EPS Next Y7.2%
EPS Next 2Y25.61%
EPS Next 3Y20.49%
EPS Next 5Y21.04%
Revenue Next Year7.3%
Revenue Next 2Y6.35%
Revenue Next 3Y25.72%
Revenue Next 5Y42.64%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AADI Yearly Revenue VS EstimatesAADI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
AADI Yearly EPS VS EstimatesAADI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AADI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AADI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AADI Price Earnings VS Forward Price EarningsAADI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AADI Per share dataAADI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

AADI's earnings are expected to grow with 20.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.61%
EPS Next 3Y20.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AADI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AADI BIOSCIENCE INC

NASDAQ:AADI (2/21/2025, 8:00:00 PM)

2.79

-0.07 (-2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/bmo
Earnings (Next)03-13 2025-03-13/amc
Inst Owners61.01%
Inst Owner Change-98.89%
Ins Owners11.42%
Ins Owner Change12.45%
Market Cap68.86M
Analysts47.5
Price Target3.06 (9.68%)
Short Float %3.23%
Short Ratio1.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.35%
Min EPS beat(2)1.43%
Max EPS beat(2)23.27%
EPS beat(4)3
Avg EPS beat(4)7.54%
Min EPS beat(4)-3.76%
Max EPS beat(4)23.27%
EPS beat(8)6
Avg EPS beat(8)9.48%
EPS beat(12)9
Avg EPS beat(12)8.71%
EPS beat(16)12
Avg EPS beat(16)6.92%
Revenue beat(2)1
Avg Revenue beat(2)2.47%
Min Revenue beat(2)-2.25%
Max Revenue beat(2)7.19%
Revenue beat(4)1
Avg Revenue beat(4)-3.79%
Min Revenue beat(4)-18.68%
Max Revenue beat(4)7.19%
Revenue beat(8)3
Avg Revenue beat(8)-1.69%
Revenue beat(12)7
Avg Revenue beat(12)204.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)84.62%
EPS NQ rev (1m)-61.22%
EPS NQ rev (3m)-27.42%
EPS NY rev (1m)-17.46%
EPS NY rev (3m)-11.98%
Revenue NQ rev (1m)0.48%
Revenue NQ rev (3m)2.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.75
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 1
EV/EBITDA N/A
EPS(TTM)-2.28
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-2.29
FCFYN/A
OCF(TTM)-2.19
OCFYN/A
SpS1.02
BVpS2.79
TBVpS2.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.98%
ROE -89.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.39%
FCFM N/A
ROA(3y)-50.74%
ROA(5y)-44.04%
ROE(3y)-60.48%
ROE(5y)-51.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1232.43%
Cap/Sales 9.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.89
Quick Ratio 4.54
Altman-Z -3.98
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)890.25%
Cap/Depr(5y)600.82%
Cap/Sales(3y)7.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.33%
EPS Next Y7.2%
EPS Next 2Y25.61%
EPS Next 3Y20.49%
EPS Next 5Y21.04%
Revenue 1Y (TTM)7.78%
Revenue growth 3Y17.53%
Revenue growth 5Y3.85%
Sales Q2Q%21.03%
Revenue Next Year7.3%
Revenue Next 2Y6.35%
Revenue Next 3Y25.72%
Revenue Next 5Y42.64%
EBIT growth 1Y8.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.68%
OCF growth 3YN/A
OCF growth 5YN/A